Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Disease-Free Survival In Renal Cancer Raises Questions, But Still Acceptable, ODAC Says

Executive Summary

Whether the endpoint can predict overall survival remains unknown, but there is no evidence not to accept it, US FDA advisory committee says.

Advertisement

Related Content

Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?
Pfizer v. Pfizer: Sutent Indication Expansion Will Hinge On Conflicting Trials
Pfizer Sutent Label Expansion May Hinge On Disease-Free Survival Stats

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS121600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel